In conclusion, our study provides profound evidence that transient inhibition of Atgl-driven lipolysis by the selective inhibitor Atglistatin corrects diet induced obesity, glucose intolerance, and fatty liver disease without causing ectopic lipid accumulation. Here, PNPLA2 is linked to obesity due to melanocortin 4 receptor deficiency.